B. Riley Wealth Advisors Inc. Purchases New Position in Sanofi $SNY

B. Riley Wealth Advisors Inc. acquired a new position in Sanofi (NASDAQ:SNY) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,806 shares of the company’s stock, valued at approximately $715,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sanofi by 32.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 200,615 shares of the company’s stock valued at $11,126,000 after acquiring an additional 48,670 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of Sanofi by 5.8% during the first quarter. Steward Partners Investment Advisory LLC now owns 63,428 shares of the company’s stock valued at $3,518,000 after purchasing an additional 3,455 shares during the last quarter. Brooklyn Investment Group lifted its position in Sanofi by 496.2% during the first quarter. Brooklyn Investment Group now owns 9,748 shares of the company’s stock valued at $541,000 after purchasing an additional 8,113 shares during the period. Finally, Northern Trust Corp boosted its holdings in Sanofi by 6.4% in the first quarter. Northern Trust Corp now owns 2,054,790 shares of the company’s stock worth $113,959,000 after purchasing an additional 124,230 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. HSBC reissued a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Trading Down 0.8%

Shares of Sanofi stock opened at $47.44 on Wednesday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06. The company has a market capitalization of $116.49 billion, a P/E ratio of 11.11, a P/E/G ratio of 1.30 and a beta of 0.44. The company has a fifty day moving average of $49.79 and a 200 day moving average of $48.98.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. The business had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s quarterly revenue was down 7.5% on a year-over-year basis. During the same period last year, the firm earned $2.25 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.